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Background: Three meta-analyses and one systematic review have been conducted on the question of whether
self-collected specimens are as accurate as clinician-collected specimens for STI screening. However, these reviews predate
2007 and did not analyze rectal or pharyngeal collection sites. Currently, there is no consensus on which sampling method
is the most effective for the diagnosis of genital chlamydia (CT), gonorrhea (GC) or human papillomavirus (HPV) infection.
Our meta-analysis aims to be comprehensive in that it will examine the evidence of whether self-collected vaginal, urine,
pharyngeal and rectal specimens provide as accurate a clinical diagnosis as clinician-collected samples (reference standard).
Methods/Design: Inclusion and exclusion criteria: Eligible studies include both randomized and non-randomized controlled
trials, pre- and post-test designs, and controlled observational studies. Search strategy: The databases that will be searched
include the Cochrane Database of Systematic Reviews, Web of Science, Database of Abstracts of Reviews of Effects (DARE),
EMBASE and PubMed/Medline. Data collection and analysis: Data will be abstracted independently by two reviewers using a
standardized pre-tested data abstraction form. Heterogeneity will be assessed using the Q2 test. Sensitivity and specificity
estimates with 95% confidence intervals as well as negative and positive likelihood ratios will be pooled and weighted using
random effects meta-analysis, if appropriate. A hierarchical summary receiver operating characteristics curve for self-collected
specimens will be generated.
Discussion: This synthesis involves a meta-analysis of self-collected samples (urine, vaginal, pharyngeal and rectal swabs)
versus clinician-collected samples for the diagnosis of CT, GC and HPV, the most prevalent STIs. Our systematic review will
allow patients, clinicians and researchers to determine the diagnostic accuracy of specimens collected by patients compared
to those collected by clinicians in the detection of chlamydia, gonorrhea and HPV.
Keywords: Self-collected, self-sampling, Physician-collected, Clinician-collected, Home sampling, Chlamydia, Gonorrhea,
Human papillomavirus (HPV), STI, Diagnosis, Gold standard, Nucleic acid amplification testsBackground
Increasing rates of sexually transmitted infections (STIs)
remain a growing concern worldwide [1-3]. Despite
active and passive surveillance and multiple interven-
tions aimed at increasing the number of cases found and
treated, genital chlamydia (CT), gonorrhea (GC) and
human papillomavirus (HPV) infections contribute to a
large burden on health resources. Strategies to control
STIs have included interventions aimed at improving* Correspondence: Carole.Lunny@bccdc.ca
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reproduction in any medium, provided the oraccess to screening among individuals who are at high
risk of acquiring STIs. Current clinical screening
methods for GC and CT involve the collection of cer-
vical (endo- and ecto-), urethral, pharyngeal and rectal
swabs. Urine and vaginal specimens are also collected
for GC and CT. HPV testing using self-collected vaginal
swabs is available but is not publicly funded, and, more-
over, clinician-testing for HPV has not been adopted in
Canada. Recent publications have identified a need for
targeted site-specific screening of the pharynx, urethra
and rectum to increase detection of cases, especially in
individuals engaging in high risk activities such as men
who have sex with men [4,5].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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samples provides a different option for screening outside
of the traditional clinical setting. Settings for self-collection
of samples for STI testing can include community-based
organizations, street outreach settings and the internet.
However, more evidence is required to determine whether
self-collected specimens are as accurate as clinician-
collected specimens in terms of diagnostic accuracy for
CT, GC and HPV, prior to recommending it as standard
practice. The purpose of our systematic review and meta-
analysis will be to examine whether a self-collected sample
is as accurate as a clinical-collected sample for the diagno-
sis of CT, GC and HPV. Our specific research question is:
Are self-collected vaginal, urine, pharyngeal and rectal
samples as accurate as clinician-collected samples for
the diagnosis of CT, GC and HPV?
Methods
Inclusion and exclusion criteria
Eligible studies will include both randomized and non-
randomized controlled trials, pre- and post-test designs,
and controlled observational studies examining self-
collected versus clinician-collected samples using the
nucleic acid amplification test (NAAT) to detect GC, CT
and HPV. All manuscripts must include a reference stand-
ard of a clinician-collected specimen. Manuscripts that
only report a kappa statistic (measuring agreement be-
tween the self-collected sample and the clinician-collected
sample) will also be reviewed. Table 1 delineates the eligi-
bility guidelines for comparing sites for self-collected sam-
ple versus clinician-collected samples. Studies will be
excluded when the time period between self- and
clinician-collected samples is longer than three weeks be-
cause the disease status of the patient may have changed.
Other reasons for exclusion are: (a) participants are known
to be positive for disease before enrolment in the study,
(b) combined test results (for example, self-collected com-
bined urine and vaginal samples) or (c) more than 20% of
included patients dropped out of the study.
Definition of reference standard
Our reference standard will be clinician-collected sam-
ples. Both self-collected and clinician-collected samples
must have used a NAAT to be included. NAATs areTable 1 Eligibility guidelines for comparing sites for self-colle
Cervical
Self-collected samples Urine Eligible
Rectal Not
Vaginal Eligible
Pharyngeal Nothighly sensitive and specific for the detection of CT and
GC when using swabs from the genital tract or first-
catch urine specimens [6]. The different NAATs for the
detection of CT and GC include: PCR testing (Abbott
LCx and Roche COBAS AMPLICOR™ (AC)), strand dis-
placement amplification (Becton Dickinson ProbeTec™
ET), transcription-mediated amplification (Amptima,
GenProbe Aptima Combo 2™ (AC2) and the Aptima
Neisseria gonorrhoeae assay), and the ligase chain reac-
tion (discontinued as of 2002) [6-8].
Dual assays that test for CT and GC, include AC2,
Becton Dickinson ProbeTec™ CT/GC, AC and Abbott
Realtime™ CT/NG assays [8-10]. The GenProbe PACE 2™,
discontinued as of December 2012, and the Digene
Corporation Hybrid Capture 2™ (HC2) are non-amplified
probe tests [11]. HPV NAAT tests in this review will be
classified as either HC2 or PCR [12,13]. Table 2 provides
the sensitivity and specificity of clinician-collected speci-
mens for GC and CT using NAATassays.
Search strategy
Our search will include English and non-English data-
bases. Our search will be limited to articles published
since 1990 because of two factors: (a) the HC2 test is the
most widely used HPV test worldwide and was first used
in 1990 [14] and (b) the oldest currently available NAAT
test reported in the literature for self-collected GC or
CT was after 1990 [15]. Our search will be conducted
on tests that ran between 1990 and June 2013. The data-
bases that will be searched include the Cochrane Data-
base of Systematic Reviews, Web of Science, Database of
Abstracts of Reviews of Effects, EMBASE and PubMed/
Medline. We have chosen not to register our protocol
with PROSPERO.
Search terms
MeSH headings, subject headings and keywords will be
created using language that describes laboratory test per-
formances for NAAT tests for GC, CT and HPV. The
scope notes of the MeSH headings and subject headings
and terms will be reviewed to identify additional terms,
common usage and previous usage for terms being
searched. Keywords in published journals will also be
used. Search terms will include but will not be limited







Table 2 Sensitivity and specificity of reference standard (clinician-collected samples) for NAAT tests of gonorrhea and
chlamydia
Vaginal swab Rectal swab Pharyngeal swab Urine
Gonorrhea
Sensitivity 96.2 [13] 44-93 [14,15] 60–95 [14,15] 98.9 [16]
Specificity 99.3 [13] 99.5 [15] 78.9 [15] 99.3 [16]
Chlamydia
Sensitivity 97.2 [13] 64–94 [14,15] 33–80 [14,15] 96.2 [16]
Specificity 95.2 [13] 100 [5] 100 [5] 98.1 [16]
Gonorrhea/chlamydia combination
Sensitivity 97.2 [13] 100 [14,15] 95 [14,15] 100 [17]
Specificity 97–99.4 [13] 98 [14] 98 [14] 98.8 [17]
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http://www.systematicreviewsjournal.com/content/2/1/93sexually transmitted infections; chlamydia; gonorrhea;
human papillomavirus/HPV; screening; testing; repro-
ductive health; adolescent health; non-clinic testing;
urine testing; vaginal testing; pharyngeal testing; self-
collected specimens; home sampling; test performance;
test accuracy; PCR, polymerase chain reaction and nu-
cleic acid amplification test sensitivity; specificity and
diagnostic ratio. Boolean combinations will be created
for more specific searches. Authors will also be asked to
identify key articles that should be included in the re-
view. The bibliographies of retrieved articles will also be
manually searched as well as key journals such as
Sexually Transmitted Infections, Sexually Transmitted
Diseases and Journal of Clinical Microbiology.
Data collection
Data will be abstracted independently by two reviewers
using a standardized pre-tested form. Any disagreements
between the reviewers will be resolved by a third re-
viewer. The following data elements will be extracted,
and if appropriate, used for stratification if heterogeneity
is found: true/false positive; true/false negative; sensitiv-
ity; specificity; reference (gold) standard used to com-
pare test characteristics; NAAT platform used; specimen
(urine, vaginal, pharyngeal or rectal); diagnostic odds ra-
tio; positive likelihood ratio; negative likelihood ratio;
kappa statistic; sex and age of participants; presence of
symptoms (if a study includes results from both symp-
tomatic and asymptomatic patients, both sets of results
will be included); HIV status; date of study initiation and
publication status (published or unpublished); country of
study and author affiliation; number of specimens ana-
lyzed; number of tests per patient; any elements of
blinding; location of self-collection (home, clinic and so
on); community type (urban, rural); sex (women, men,
transsexual); population type (stable, homeless); sexual
orientation (gay, heterosexual, bisexual, transgendered);
religion; clinician setting (outreach, primary care, refer-
ral); HPV type (high, low or both) and prevalence. Ifstudies involve several self-sampling methods, the first
method described will be used in the analysis. We con-
sider any high-risk HPV positive test as standard; however,
if the authors have not separated high- and low-risk HPV
types, we used their combined data.
Data analysis
The numbers of true positives, false negatives, false posi-
tives and true negatives will be extracted from each study,
and test sensitivity and specificity as well as likelihood ra-
tios will be calculated. Coupled forest plots for paired sen-
sitivity and specificity for each study along with 95%
confidence intervals will be created in RevMan 5.0 to de-
tect publication bias, if present. A meta-analysis will be
conducted according to the Cochrane Collaboration’s new
recommended methodology for systematic reviews of
Diagnostic Test Accuracy [16]. Hierarchical summary re-
ceiver operating characteristics (HSROC) analysis will be
used, as described by Rutter and Gatsonis [17], as well as a
bivariate random effects model for comparison purposes
[18]. The HSROC model will be created, using SAS ver-
sion 19, to provide a general framework for the meta-
analysis and to allow for the calculation of the summary
receiver operating characteristics (SROC) as well as the
expected operating point on the curve and summary esti-
mates of paired sensitivity and specificity (and positive/
negative likelihood ratios). The HSROC will also be used
to investigate heterogeneity between studies by taking into
account both within- and between-study variability. Plots
will not be fitted if there are four studies or less, as there
will not be enough data to fit the hierarchical models with
all five parameters by maximum likelihood. The Q statistic
will be used to test for heterogeneity and publication bias
will be examined. If heterogeneity is detected then the
data will be examined to determine if stratification is ap-
propriate. Studies will be stratified based on sub-grouping
from data extraction. If heterogeneity is still evident
pooled analyses will not be done and a descriptive sum-
mary will be reported.
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Validity will be assessed using the Quadas-2 (Quality
Assessment of Diagnostic Accuracy Studies) checklist
[19]. Sensitivity analyses will be conducted to investigate
the effect of outliers on the summary estimates. The
Cochrane Collaboration approach with risk of bias tables
will be used to classify the studies as high, low or unclear
[20]. The overall risk of bias for an individual study will be
categorized as low if the risk of bias is low in all domains,
unclear if the risk of bias is unclear in at least one domain
without any high risk of bias domains or high if the risk of
bias is high in at least one domain. The risk bias assess-
ment will be performed by two reviewers independently
and disagreements resolved by consensus.
Discussion
Scoping review
A search of the Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects, EMBASE and
PubMed/Medline using a review filter was conducted
using the terms self-sampling and noninvasive sampling.
One previous 2005 systematic review [21] evaluated 29 ar-
ticles that reported sensitivity and specificity of urine-
based NAATs for CT and GC with the specific aim of
comparing self-collected urine samples with clinician-
collected cervical and urethral samples. They reported
congruent test accuracies between self-collection and
physician-collected samples for CT, but lower sensitivity
for GC in self-collected cervical samples compared to
clinician-collected samples. This systematic review lacks
information on pooled estimates of rectal or pharyngeal
specimens. In addition, this review was published in 2005
and NAAT platforms have since changed significantly,
and there are now platforms with greater test performance
[7]. Dual assays, which test for both CT and GC, are now
available [8,9]. Three other meta-analyses were conducted
on the accuracy of self-collected vaginal specimens for
diagnosing HPV compared to clinician-collected samples
[22-24]; however, these reviews were conducted prior to
2007 and need updating. Moreover, these reviews did not
include the rectum or pharyngeal anatomical sites as col-
lection sites for specimens.
Significance of the review
Increasing rates of STIs remain a growing concern in
British Columbia, Canada, and worldwide. Rates of STIs
continue to grow despite active and passive surveillance
and multiple interventions aimed at increasing the num-
ber of cases found and treated. New interventions, such
as self-collected sampling, are needed to identify STIs
and stop the upward trend.
Reported rates of genital chlamydia (CT) have steadily
increased in British Columbia since 1998, from 122/
100,000 (1998) to 255/100,000 (2011), with the majorityof cases being in females between the ages of 15 and 24
[2]. CT rates for young men in BC have also doubled
since 1999 [1]. Similarly, the rate of gonorrhea infections
has increased since 1998, from 529 new reported cases
in 1998 to 1,573 new cases in 2011 [1,2]. The increased
rates of GC and CT heighten concerns of increased rates
of pelvic inflammatory disease, and vulnerability to ac-
quiring HIV [2]. In addition, HPV is widespread in
Canada and worldwide and persistent infection is corre-
lated with an increased risk of cervical cancer [25,26].
The prevalence of HPV among women aged 13 to 86 is
estimated to be 16.8% (with 10.7% being subtype 16 or 18
[27], which are the sub-types that cause 70% of cervical
cancers [28]). The prevalence of HPV in men is less clear
but cross-sectional studies of men in Vancouver found up
to 27% of men have HPV subtype 16 or 18 [29,30].
Barriers to accessing care
Uptake of STI testing remains a public health challenge,
with particularly low testing rates among young men
(age < 25) and gay, bisexual and other men who have sex
with men (MSM) [30-37]. Stigma, shame, negative inter-
actions with service providers, concerns about privacy
and confidentiality, inaccessible locations, hours of oper-
ation, transportation costs and inconvenience have been
identified as STI testing barriers [38-40]. In addition, not
having a primary care provider [36] and fear of disclos-
ing risky sexual behaviors to a care provider [37,41] have
been shown to be factors that inhibit STI testing in some
settings, especially for youths. Strategies to remove bar-
riers to testing have been developed, such as internet-
based testing using self-collected samples [42-44] or
community-based screening for hard-to-reach popula-
tions [45,46].
Models of internet-based self-sampling
A number of models for internet-based testing have
been developed, all typically including an online risk
self-assessment, test recommendations and specimen
collection without requiring presentation to a clinic [47].
Self-collected specimens are taken in a community
laboratory or at home [48-50]. The Clinical Prevention
Services Division at the BC Centre for Disease Control
is developing an internet-based testing program called
GetCheckedOnline, aimed at decreasing barriers to STI
and HIV testing with an emphasis on youth and MSM.
Focus group discussions with youths, MSM and STI
clinic clients revealed that they would use the internet-
based testing service or recommend it to others [51].
The inclusion of self-collected specimens as part of this
program is being considered [5]; however, knowing the
accuracy of self-collection specimens compared to
clinician-collected specimens for the diagnosis of STIs is
required prior to adoption of this program. Ultimately,
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be to make screening more accessible, increase the num-
ber of people being tested, reduce onward transmission
and provide timely treatment.
Cost-effectiveness
Self-collected samples are also potentially more cost
effective compared to clinician-collected samples.
Organizing samples through the internet can reduce
health service and delivery costs as interventions deliv-
ered over the internet are likely to cost less than treat-
ments requiring frequent contact with health-care
professionals [52]. Huang and colleagues [53] modelled
an internet-based self-sampling chlamydia screening
program for young women compared to a clinic-based
screening and concluded that the internet-based screen-
ing strategy prevented 35.5 more cases of pelvic inflam-
matory disease and saved an additional US $41,000 in
direct medical costs compared with the clinic-based
screening strategy. A similar study found that self-
obtained vaginal sampling for chlamydia detection was
the least expensive and the most cost-effective method
compared to clinician-collected or urine samples,
preventing 17 more cases of pelvic inflammatory disease
[54]. A third US study found that the lifetime cost of in-
home self-collection for detection of high-risk HPV
followed by in-clinic cytology triage was slightly lower
than clinician-based screening [55].
The outcomes of this systematic review and meta-
analysis are important in the detection of STI disease in
hard-to-reach populations, in particular, those who may
be unwilling to provide samples in traditional settings.
The aim of exploring whether self-collected samples
have comparable specificity and sensitively to samples
collected in traditional settings has the potential to in-
crease testing rates. Presumably, with higher testing
levels, transmission could be reduced. Our systematic re-
view will allow patients, clinicians and researchers to de-
termine the diagnostic accuracy of specimens collected
by patients compared to those collected by clinicians in
the detection of chlamydia, gonorrhea, and HPV.
Abbreviations
CT: Genital chlamydia; GC: Gonorrhea; HPV: Human papillomavirus;
HSROC: Hierarchical summary receiver operating characteristics; MSM: Men
who have sex with men; NAAT: Nucleic acid amplification test;
PCR: Polymerase chain reaction; SROC: Summary receiver operating
characteristics; STI: Sexually transmitted infection.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DT and NL drafted the manuscript. CL edited and finalized the manuscript.
GO, RL and MG contributed to the research design. DT, CL, GO, MG, LH, MK
and TW participated in writing the grant application and edited the
manuscript. All authors read and approved the final manuscript.Acknowledgements
We thank the Canadian Institutes of Health Research (CIHR) for funding this
research. The funding body had and will have no role in the design of the
study; in the collection, analysis, and interpretation of the data; in the writing of
the manuscript and in the decision to submit the manuscript for publication.
Author details
1BC Centre for Disease Control, 655 West 12th Avenue, Vancouver, BC V5Z
4R4, Canada. 2University of British Columbia, 2329 W Mall, Vancouver, BC V6T
1Z4, Canada. 3Public Health Agency of Canada, 130 Colonnade Road, A.L.
6501H, Ottawa, ON K1A 0K9, Canada.
Received: 22 July 2013 Accepted: 1 October 2013
Published: 10 October 2013
References
1. STI Prevention and Control: STI/HIV Prevention and Control: 2009 Annual
Surveillance Report. Vancouver, BC: BC Centre for Disease Control; 2009:2009.
2. Mayaud P, McCormick D: Interventions against sexually transmitted
infections (STI) to prevent HIV infection. Br Med Bull 2001, 58:129–153.
3. BC Centre for Disease Control: STI in British Columbia: 2011 Annual
Surveillance Report. Vancouver, BC: BC Centre for Disease Control; 2011.
http://www.bccdc.ca/util/about/annreport/default.htm.
4. Dodge B, Van Der Pol B, Rosenberger JG, Reece M, Roth AM, Herbenick D,
Fortenberry JD: Field collection of rectal samples for sexually transmitted
infection diagnostics among men who have sex with men. Int J STD AIDS
2010, 21(4):260–264.
5. Gilbert M, Salway Hottes T, Chabot C, Haag D, Shoveller J, Ogilvie G: ‘There are
a million scenarios to consider’: health care provider perspectives on internet-based
testing for sexually transmitted infections, HIV and hepatitis C in British Columbia,
Poster for STI & AIDS World Congress 2013. Vienna, Austria; 2013.
6. Moncada J, Donegan E, Schachter J: Evaluation of CDC-recommended
approaches for confirmatory testing of positive Neisseria gonorrhoeae
nucleic acid amplification test results. J Clin Microbiol 2008, 46(5):1614–1619.
7. Schachter J, Hook EW, Martin DH, Willis D, Fine P, Fuller D, Jordan J, Janda
WM, Chernesky M: Confirming positive results of nucleic acid
amplification tests (NAATs) for Chlamydia trachomatis: all NAATs are not
created equal. J Clin Microbiol 2005, 43(3):1372–1373.
8. Gaydos CA, Quinn TC, Willis D, Weissfeld A, Hook EW, Martin DH, Ferrero
DV, Schachter J: Performance of the APTIMA combo 2 assay for detection
of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and
endocervical swab specimens. J Clin Microbiol 2003, 41(1):304–309.
9. Gaydos CA, Cartwright CP, Colaninno P, Welsch J, Holden J, Ho SY, Webb
EM, Anderson C, Bertuzis R, Zhang L, Miller T, Leckie G, Abravaya K,
Robinson J: Performance of the Abbott RealTime CT/NG for detection of
Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol 2010,
48(9):3236–3243.
10. Schachter J: Which test is best for chlamydia? Curr Opin Infect Dis 1999,
12(1):41–45.
11. Darwin LH, Cullen AP, Crowe SR, Modarress KJ, Willis DE, Payne WJ:
Evaluation of the hybrid capture 2 CT/GC DNA tests and the GenProbe
PACE 2 tests from the same male urethral swab specimens. Sex Transm
Dis 2002, 29(10):576–580.
12. Eide ML, Debaque H: HPV detection methods and genotyping techniques
in screening for cervical cancer. Ann Pathol 2012, 32(6):e15–e23.
13. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M: Nucleic acid tests for the
detection of alpha human papillomaviruses. Vaccine 2012, 30(Suppl 5):F100–F106.
14. Qiagen: Hybrid Capture 2 Versus PCR: Are All HPV Tests Created Equal?; 2013. http://
www.qiagen.com/Knowledge-and-Support/Webinars/Molecular-Diagnostics/
AttilaLorinczHC2/.
15. Hobbs MM, van der Pol B, Totten P, Gaydos CA, Wald A, Warren T, Winer RL,
et al: From the NIH: proceedings of a workshop on the importance of
self-obtained vaginal specimens for detection of sexually transmitted
infections. Sex Transm Dis 2008, 35(1):8–13.
16. Diagnostic Test Accuracy Working Group: Handbook for DTA Reviews.
Birmingham UK: Cochrane Collaboration, Wiley Publications; 2011.
17. Rutter CM, Gatsonis CA: A hierarchical regression approach to meta-analysis
of diagnostic test accuracy evaluations. Stat Med 2001, 20(19):2865–2884.
18. Dubourg J, Berhouma M, Cotton M, Messerer M: Meta-analysis of
diagnostic test accuracy in neurosurgical practice. Neurosurg Focus 2012,
33(1):e5.
Taylor et al. Systematic Reviews 2013, 2:93 Page 6 of 6
http://www.systematicreviewsjournal.com/content/2/1/9319. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al:
QUADAS-2: a revised tool for the quality assessment of diagnostic
accuracy studies. Ann Intern Med 2011, 155(8):529–536.
20. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of
Interventions Version 5.0.1. Cambridge, UK: Cochrane Collaboration, Wiley
Publications; 2008.
21. Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB: Systematic
review: noninvasive testing for Chlamydia trachomatis and Neisseria
gonorrhoeae. Ann Intern Med 2005, 142(11):914–925.
22. Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, Petric M, Chambers K, White R,
FitzGerald JM: Diagnostic accuracy of self collected vaginal specimens for
human papillomavirus compared to clinician collected human papillomavirus
specimens: a meta-analysis. Sex Transm Infect 2005, 81(3):207–212.
23. Petignat P, Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F: Are self-
collected samples comparable to physician-collected cervical specimens
for human papillomavirus DNA testing? A systematic review and meta-
analysis. Gynecol Oncol 2007, 105(2):530–535.
24. Stewart DE, Gagliardi A, Johnston M, Howlett R, Barata P, Lewis N, Oliver T,
Mai V, HPV Guidelines Panel: Self-collection guidelines panel. Self-
collected samples for testing of oncogenic human papillomavirus: a
systematic review. J Obstet Gynaecol Can 2007, 10:817–828.
25. Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA: Epidemiology and costs
associated with genital warts in Canada. Sex Transm Infect 2009,
85(2):111–115.
26. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G,
Edmunds WJ, Claeys P, Goldenthal KL, Harper DM, Markowitz L: Human
papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007,
85(9):719–726.
27. Moore RA, Ogilvie G, Fornika D, Moravan V, Brisson M, Amirabbasi-Beik M,
Kollar A, Burgess T, Hsu R, Towers L, Lo J, Matisic J, Brooks-Wilson A:
Prevalence and type distribution of human papillomavirus in 5,000
British Columbia women – implications for vaccination. Cancer Causes
Control 2009, 20(8):1387–1396.
28. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D,
Shah KV, Meijer CJ: Against which human papillomavirus types shall we
vaccinate and screen? The international perspective. Int J Cancer 2004,
111(2):278–285.
29. Ogilvie GS, Taylor DL, Achen M, Cook D, Krajden M: Self-collection of
genital human papillomavirus specimens in heterosexual men.
Sex Transm Infect 2009, 85(3):221–225.
30. Rank C, Gilbert M, Kwag M, Severini A, van Niekerk D, Ogunnaike-Cooke S,
Kropp R, Gustafson R, Moore D, Ogilvie G, the ManCount Survey Team:
Prevalence of Rectal Human Papilloma Virus Infection Among Men Who Have
Sex With Men in Vancouver. Vancouver, BC, Canada: Vancouver Coastal
Health; 2010.
31. Canada H: Canada Communicable Disease Report 29–19. Ottawa, ON:
Scientific Publication and Multimedia Services; 2003.
32. Wong T, Singh A, Mann J, Hansen L, McMahon S: Gender differences in
bacterial STIs in Canada. BMC Womens Health 2004, 4(Suppl 1):S26.
33. Lewis DA: Improving men’s sexual health: a challenge for today. Sex
Transm Infect 2004, 80(6):423–424.
34. Moses S, Elliott L: Sexually transmitted diseases in Manitoba: evaluation of
physician treatment practices, STD drug utilization, and compliance with
screening and treatment guidelines. Sex Transm Dis 2002, 29(12):840–846.
35. Berry SA, Ghanem KG, Page KR, Thio CL, Moore RD, Gebo KA: Gonorrhoea
and chlamydia testing rates of HIV-infected men: low despite guidelines.
Sex Transm Infect 2010, 86(6):481–484.
36. Mimiaga MJ, Reisner SL, Bland S, Skeer M, Cranston K, Isenberg D, Vega BA, Mayer
KH: Health system and personal barriers resulting in decreased utilization of
HIV and STD testing services among at-risk black men who have sex with
men in Massachusetts. AIDS Patient Care STDS 2009, 23(10):825–835.
37. Shoveller J, Johnson J, Rosenberg M, Greaves L, Patrick DM, Oliffe JL, Knight
R: Youth’s experiences with STI testing in four communities in British
Columbia. Canada. Sex Transm Infect 2009, 85(5):397–401.
38. Fortenberry JD: Health care seeking behaviors related to sexually transmitted
diseases among adolescents. Am J Public Health 1997, 87(3):417–420.
39. Evans SJ, Wright BL, Goodbrand L, Kilbreath JP, Young J: Teen sexuality.
Reaching out in the malls. Can J Public Health 2002, 93(1):47–51.
40. Goldenberg S, Shoveller J, Koehoorn M, Ostry A: Barriers to STI testing
among youth in a Canadian oil and gas community. Health Place 2008,
14(4):718–729.41. Klein JD, Wilson KM: Delivering quality care: adolescents’ discussion of
health risks with their providers. J Adolesc Health 2002, 30(3):190–195.
42. Chai SJ, Aumakhan B, Barnes M, Jett-Goheen M, Quinn N, Agreda P, Whittle
P, Hogan T, Jenkins WD, Rietmeijer CA, Gaydos CA: Internet-based
screening for sexually transmitted infections to reach nonclinic
populations in the community: risk factors for infection in men.
Sex Transm Dis 2010, 37(12):756–763.
43. Prestage GP, Hudson J, Jin F, Corrigan N, Martin P, Grulich AE, McInnes D:
Testing for HIV and sexually transmissible infections within a mainly
online sample of gay men who engage in group sex. Sex Transm Infect
2009, 85(1):70–74.
44. Blas MM, Alva IE, Cabello R, Garcia PJ, Carcamo C, Redmon M, Kimball AM,
Ryan R, Kurth AE: Internet as a tool to access high-risk men who have sex
with men from a resource-constrained setting: a study from Peru.
Sex Transm Infect 2007, 83(7):567–570.
45. Auerswald CL, Sugano E, Ellen JM, Klausner JD: Street-based STD testing
and treatment of homeless youth are feasible, acceptable and effective.
J Adolesc Health 2006, 38(3):208–212.
46. Kahn RH, Moseley KE, Thilges JN, Johnson G, Farley TA: Community-based
screening and treatment for STDs: results from a mobile clinic initiative.
Sex Transm Dis 2003, 30(8):654–658.
47. Robinson TN, Patrick K, Eng TR, Gustafson D: An evidence-based approach
to interactive health communication: a challenge to medicine in the
information age. Science panel on interactive communication and
health. JAMA 1998, 280(14):1264–1269.
48. Gaydos CA, Dwyer K, Barnes M, Rizzo-Price PA, Wood BJ, Flemming T,
Hogan MT: Internet-based screening for Chlamydia trachomatis to reach
non-clinic populations with mailed self-administered vaginal swabs.
Sex Transm Dis 2006, 33(7):451–457.
49. Gaydos CA, Barnes M, Aumakhan B: Males will submit self-obtained penile
swabs for the detection of Chlamydia trachomatis when recruited via the
internet: acceptability and accuracy. J Adolesc Health 2009, 44(2 suppl):S9.
50. Woodruff A, Levine DK, Klausner JD: Expanded STDtest.org Provides San
Franciscans With Free Testing and Secure Online Results for five STDs. National
STD Conference: Chicago, IL; 2008.
51. Hottes TS, Farrell J, Bondyra M, Haag D, Shoveller J, Gilbert M: Internet-
based HIV and sexually transmitted infection testing in British Columbia,
Canada: opinions and expectations of prospective clients. J Med Internet
Res 2012, 14(2):e41.
52. Tate DF, Finkelstein EA, Khavjou O, Gustafson A: Cost effectiveness of
internet interventions: review and recommendations. Ann Behav Med
2009, 38(1):40–45.
53. Huang W, Gaydos CA, Barnes MR, Jett-Goheen M, Blake DR: Cost-
effectiveness analysis of Chlamydia trachomatis screening via internet-
based self-collected swabs compared with clinic-based sample
collection. Sex Transm Dis 2011, 38(9):815–820.
54. Blake DR, Maldeis N, Barnes MR, Hardick A, Quinn TC, Gaydos CA:
Cost-effectiveness of screening strategies for Chlamydia trachomatis
using cervical swabs, urine, and self-obtained vaginal swabs in a sexually
transmitted disease clinic setting. Sex Transm Dis 2008, 35(7):649–655.
55. Balasubramanian A, Kulasingam SL, Baer A, Hughes JP, Myers ER, Mao C,
Kiviat NB, Koutsky LA: Accuracy and cost-effectiveness of cervical cancer
screening by high-risk human papillomavirus DNA testing of self-collected
vaginal samples. J Low Genit Tract Dis 2010, 14(3):185–195.
doi:10.1186/2046-4053-2-93
Cite this article as: Taylor et al.: Self-collected versus clinician-collected
sampling for sexually transmitted infections: a systematic review and
meta-analysis protocol. Systematic Reviews 2013 2:93.
